Search filters
Filters
Clear All

Phase

  • 5
  • 3
  • 6
  • 7
  • 1
  • 37
  • 61
  • 35
  • 1
  • 60

Found 61 Lung Disease trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

BEACON-IPF

99 years and younger
All genders
This phase 3 study will evaluate bexotograst in patients with IPF. The study will include a CT, PEs, lung function testing, EKGs, vital signs, questionnaires, and safety labs, as well as PK and PD testing.
Learn More

UPCC 04522: Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

99 years and younger
All genders
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
Learn More

UPCC 02522 A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (

99 years and younger
All genders
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Learn More

IMPAHCT:

99 years and younger
All genders
This phase 2b/3 study will use AV-101 dry powder for oral inhalation in patients with PAH. Procedures include PEs, vital signs, safety labs, right heart caths, echocardiograms, QOL questionnaires, 6MWTs, lung function tests, and PK labs.
Learn More

ACT18018

99 years and younger
All genders
This study will look at the efficacy, safety, and tolerability of itepekimab, in people with non-cystic fibrosis bronchiectasis. Patients will be asked to complete a CT, lab tests, safety labs, lung function tests, PEs, ECGs, and questionnaires.
Learn More

4DMT

99 years and younger
All genders
The objectives of this Phase 1/2 prospective interventional trial are to: 1. Evaluate the safety, tolerability, and immunogenicity of a single dose of 4D-710 delivered via nebulization 2. Identify a recommended phase 2 dose (RP2D) for further evaluation 3. Evaluate 4D-710 target gene transduction/expression in bronchoscopic samples (Dose Exploration) and …
Learn More

EFC17801

99 years and younger
All genders
The study will investigate the eficacy and safety of belumosudil compared with placebo, administered on top of azithromycin and SOC regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, at least 18 years age and with progressive CLAD despite azithromycin.
Learn More

UPCC 23922 A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of H

99 years and younger
All genders
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Learn More

MK7684A-008

99 years and younger
All genders
This study evaluates the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer.
Learn More

1305-0031

99 years and younger
All genders
This is an OLE for all subjects we currently have enrolled in BI 1305-0014 and 1305-0023. Subjects will be on either 9 mg or 18 mg of IP based on results from the current studies. Procedures involve safety labs, lung function testing, clinical labs, ECGs, PEs, AE collection.
Learn More
41 - 50 of 61